RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) Stock Short Interest Jumps 205.4%

RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) was the target of a significant growth in short interest during the month of September. As of September 15th, there was short interest totaling 623 shares, a growth of 205.4% from the August 31st total of 204 shares. Based on an average trading volume of 196 shares, the short-interest ratio is currently 3.2 days. Currently, 0.1% of the shares of the company are sold short.

RCN Pareto Strategic Allocation ETF Price Performance

PRTO stock traded up $0.07 on Friday, reaching $27.58. The company’s stock had a trading volume of 311 shares. RCN Pareto Strategic Allocation ETF has a 52 week low of $24.68 and a 52 week high of $28.58. The company has a market capitalization of $17.38 million, a P/E ratio of -28.73 and a beta of -1.16. The business has a fifty day simple moving average of $27.84.

Proteon Therapeutics was a biopharmaceutical company focused on developing treatments for patients with kidney and vascular diseases. The company’s research and development efforts centered on therapies designed to address severe and life-threatening conditions, particularly those related to renal disease and vascular access for hemodialysis patients.

One of Proteon Therapeutics’ best-known product candidates was vonapanitase, an investigational enzyme developed to improve vascular access outcomes in patients with end-stage renal disease who require hemodialysis.